论文部分内容阅读
目的:观察至灵胶囊佐治哮喘的临床疗效。方法:选取我院2013年10月—2014年10月由呼吸科门诊及病房诊治的支气管哮喘病人110例,随机分为观察组和对照组,两组均给予糖皮质激素、氨茶碱、β受体激动剂等基础治疗,观察组加服至灵胶囊,观察两组临床疗效、一秒用力呼气容积(FEV_1)、用力肺活量(FVC)及FEV_1/FVC(FEV_1%)等肺功能指标及IgE等血清免疫学指标。结果:观察组治疗总有效率显著高于对照组(P<0.05);治疗后肺功能改善情况,观察组优于对照组(P<0.05);治疗后血清IgE下降程度,观察组较对照组下降尤为明显(P<0.05)。结论:至灵胶囊用于支气管哮喘效果显著,且安全可靠。
Objective: To observe the clinical efficacy of Zhiling Capsule in treating asthma. Methods: A total of 110 patients with bronchial asthma diagnosed and treated by Respiratory Clinic and Ward from October 2013 to October 2014 in our hospital were randomly divided into observation group and control group. Both groups were given glucocorticoid, aminophylline, β Receptor agonist and other basic treatment. The observation group was served with Zhiling capsule. The clinical efficacy, FEV 1, FVC and FEV 1% of the two groups were observed. IgE and other serum immunological indicators. Results: The total effective rate in the observation group was significantly higher than that in the control group (P <0.05). After treatment, the lung function was improved in the observation group and the observation group was better than the control group (P <0.05) Decline was particularly significant (P <0.05). Conclusion: Zhi Ling Capsule is effective for bronchial asthma and is safe and reliable.